...
首页> 外文期刊>Cancer Cell >DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias
【24h】

DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias

机译:DNMT3A损失驱动FLT3-ITD相关性白血病中的增强子低甲基化

获取原文
获取原文并翻译 | 示例
           

摘要

DNMT3A, the gene encoding the de novo DNA methyltransferase 3A, is among the most frequently mutated genes in hematologic malignancies. However, the mechanisms through which DNMT3A normally suppresses malignancy development are unknown. Here, we show that DNMT3A loss synergizes with the FLT3 internal tandem duplication in a dose-influenced fashion to generate rapid lethal lymphoid or myeloid leukemias similar to their human counterparts. Loss of DNMT3A leads to reduced DNA methylation, predominantly at hematopoietic enhancer regions in both mouse and human samples. Myeloid and lymphoid diseases arise from transformed murine hematopoietic stem cells. Broadly, our findings support a role for DNMT3A as a guardian of the epigenetic state at enhancer regions, critical for inhibition of leukemic transformation.
机译:DNMT3A是从头DNA甲基转移酶3A编码的基因,是血液系统恶性肿瘤中最常见的突变基因之一。但是,DNMT3A正常抑制恶性肿瘤发展的机制尚不清楚。在这里,我们表明DNMT3A的损失与FLT3内部串联复制以剂量影响的方式协同作用,以产生与人类相似的快速致死性淋巴样或髓样白血病。 DNMT3A的缺失导致DNA甲基化减少,主要是在小鼠和人类样品中的造血增强子区域。髓样和淋巴样疾病源于转化的小鼠造血干细胞。广泛地,我们的发现支持DNMT3A作为增强子区域表观遗传状态的保护者的作用,这对于抑制白血病转化至关重要。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号